Copyright 2024
| PMID | Allele | Disease | Population | Drug Names | SNP | Class | Sentence |
|---|---|---|---|---|---|---|---|
| 29259327 | HLA-A*02 | scrub typhus | NA | NA | NA | unclassified | |
| finally, we identified hla-a*0201-restricted and highly conserved cd8 t-cell epitopes in the tsa56 antigen, which may be valuable tools for assessing cellular immunity against o. tsutsugamushi and developing an effective scrub typhus vaccine. | |||||||
| 23953920 | HUMAN LEUKOCYTE ANTIGEN (HUMAN LEUKOCYTE ANTIGEN) | acute lung injury | NA | NA | NA | unclassified | |
| we performed a retrospective, single-center cohort study and identified cases of acute amr based on the presence of circulating donor-specific human leukocyte antigen (hla) antibodies (dsa), histologic evidence of acute lung injury, c4d deposition and clinical allograft dysfunction. | |||||||
| 7924371 | HLA-DR (HLA-DR) | severe sepsis | NA | NA | NA | lack_of_evidence | |
| monocyte hla-dr expression, significantly decreased in patients with severe sepsis, was correlated both with il-6 (p < .005) and il-8 concentrations (p < .001). | |||||||
| 11497155 | HLA-DR (HLA-DR) | severe sepsis | NA | NA | NA | unclassified | |
| thirty-five patients admitted with severe sepsis.measurementsanalysis of peripheral blood on admission and 48 h later of the absolute white cell count and the immunophenotype of lymphocyte (cd3, cd3-hladr, cd4, cd8, cd4/cd8 ratio, cd19, and cd25) and monocyte (cd13, cd13-hladr, cd14, cd14-hladr, cd13-cd14, and cd4) subpopulations. | |||||||
| 11497155 | HLA-DR (HLA-DR) | severe sepsis | NA | NA | NA | positive | |
| a single blood sample test obtaining the absolute monocyte and cd13-hladr subpopulation count in the first days of admission could contribute to simplifying the classification of patients with severe sepsis into high- and low-mortality risk. | |||||||
| 12595977 | HLA-DR (HLA-DR) | severe sepsis | NA | NA | NA | only_studied | |
| to evaluate the effect of recombinant human granulocyte-macrophage colony-stimulating factor (rhgm-csf) on immunoparalysis as defined by a sustained decrease of hla-dr expression on monocytes in patients with severe sepsis.designprospective, non-randomised observational study. | |||||||
| 12595977 | HLA-DR (HLA-DR) | severe sepsis | NA | NA | NA | unclassified | |
| nine consecutive patients with severe sepsis and a documented hla-dr expression on peripheral monocytes of less than 150 mean fluorescence intensity (mfi) over a period of at least 48 h prior to intervention.measurements and mean mfi was 69.4+/-13.2 24 h before and 56.7+/-8.2 on the day of the administration of 5 micro g/kg rhgm-csf. | |||||||
| 19620056 | HLA-DR (HLA-DR) | severe sepsis | NA | NA | NA | unclassified | |
| [human leucocyte antigen-dr expression on cd(14)(+) monocytes and its relationships with multiple organ dysfunction syndrome in severe sepsis]. | |||||||
| 19620056 | HLA-DR (HLA-DR) | severe sepsis | NA | NA | NA | unclassified | |
| to explore the changes of cd(14)(+) monocyte human leucocyte antigen dr (hla-dr) and their relationship with multiple organ dysfunction syndrome (mods) in severe sepsis. | |||||||
| 19620056 | HLA-DR (HLA-DR) | multiple organ dysfunction syndrome | NA | NA | NA | unclassified | |
| to explore the changes of cd(14)(+) monocyte human leucocyte antigen dr (hla-dr) and their relationship with multiple organ dysfunction syndrome (mods) in severe sepsis. | |||||||
Copyright 2024